Assistance Publique - Hôpitaux de Paris

The present invention relates to the field of anticancer treatment and concerns new populations of T cells, as blood markers to predict toxicity or effectiveness of immune checkpoint blockade (ICB)-based therapy in patients with cancer.

Method implemented by a computer for determining at least one optimal drug dosing regimen to treat a patient (2) efficiently against at least one drug-sensitive pathogenic agent responsible for infection, said method comprising the following steps:a. obtaining patient-related data related to said patient (2), such as birth date, gender, weight, creatinemia, and co-treatments;b. obtaining drug-related data, said drug-related data including parameters selected from :i. the drug, the route of administration when several routes exist for said drug and the adaptation type as "a posteriori" or "a priori" ;ii. the drug treatment regimen;wherein the process comprises a next step of:c. determine values for pharmacokinetic parameter for efficacy PPE and pharmacokinetic parameter for toxicity PPT from the patient related data, the drug related data and at least one population pharmacokinetic model for "a priori" adaptation and for "a posteriori" adaptation, when PPE and PPT are not obtained directly with the measured concentration(s);d. obtaining infection related data comprising parameters selected from the documentation of infection, the infection localization, the type of infection, the pathogen if identified, the susceptibility of the pathogen to the antifungigram/antibiogram, and the MIC if determined;wherein the process further comprises next steps of:e. Determination of an efficacy target for the drug from at least the infection related data;f. Determination of a target at risk of toxicity; and,g. Determination of at least one optimal dosing regimen of the drug by comparison of pharmacokinetic parameter of efficacy PPE with the efficacy target and the pharmacokinetic parameter of toxicity PPT with the risk of toxicity target.

L'ensemble médical (1) comprend :- un réservoir (3) hermétique amovible, contenant un médicament liquide, et comportant un orifice de distribution obturable et une cheminée traversante,- un plateau de chauffe (17), disposé sous le réservoir, comprenant une cavité de réception (18), ouverte sur le dessus et équipée d'une résistance chauffante,- un arbre (13) vertical, entrainé en rotation par un moteur (14), sur lequel est monté le réservoir qui pivote entre une position de distribution et une position d'inhalation,- une interface d'inhalation (6) buccale ou nasale.En position de distribution, l'orifice de distribution est ouvert et surplombe la cavité de réception afin de la remplir de médicament. En position d'inhalation, l'orifice de distribution est fermé et la cheminée surplombe la cavité de réception. En chauffant, la résistance forme l'aérosol qui traverse la cheminée pour atteindre l'interface d'inhalation.

The present invention belongs to the field of disease therapy, and more specifically to the field of cancer therapy. In particular, the present invention belongs to a method for determining the sensitivity of a condition, preferably cancer, to a therapeutic agent and/or a method for determining whether a subject suffers from immune ageing and/or immunosenescence.

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …